These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 432634)

  • 1. Carcinogenicity of phenacetin.
    Tomatis L
    Science; 1979 Apr; 204(4389):129-30. PubMed ID: 432634
    [No Abstract]   [Full Text] [Related]  

  • 2. Phenacetin and analgesic mixtures containing phenacetin.
    National Toxicology Program
    Rep Carcinog; 2011; 12():340-1. PubMed ID: 21863078
    [No Abstract]   [Full Text] [Related]  

  • 3. Phenacetin and analgesic mixtures containing phenacetin.
    Rep Carcinog; 2004; 11():III212-3. PubMed ID: 21089942
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of CYP1A2 in the toxicity of long-term phenacetin feeding in mice.
    Peters JM; Morishima H; Ward JM; Coakley CJ; Kimura S; Gonzalez FJ
    Toxicol Sci; 1999 Jul; 50(1):82-9. PubMed ID: 10445756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Xpa-deficient transgenic mouse model for short-term carcinogenicity testing: 9-month studies with haloperidol, reserpine, phenacetin, and D-mannitol.
    Lina BA; Woutersen RA; Bruijntjes JP; van Benthem J; van den Berg JA; Monbaliu J; Thoolen BJ; Beems RB; van Kreijl CF
    Toxicol Pathol; 2004; 32(2):192-201. PubMed ID: 15200157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose selection for carcinogenicity studies of pharmaceuticals: systemic exposure to phenacetin at carcinogenic dosage in the rat.
    Bergman K; Olofsson I; Sjöberg P
    Regul Toxicol Pharmacol; 1998 Dec; 28(3):226-9. PubMed ID: 10049794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the form of the cell growth rate function of the two-stage model for carcinogenesis.
    Charnley G; Wilson JD
    Prog Clin Biol Res; 1991; 369():291-301. PubMed ID: 1946526
    [No Abstract]   [Full Text] [Related]  

  • 8. Eighteen month oral study of aspirin, phenacetin and caffeine, in C57Bl/6 mice.
    Macklin AW; Szot RJ
    Drug Chem Toxicol; 1980; 3(2):135-63. PubMed ID: 7227215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenacetin.
    National Toxicology Program
    Rep Carcinog; 2002; 10():193. PubMed ID: 15328592
    [No Abstract]   [Full Text] [Related]  

  • 10. Analgesic mixtures containing phenacetin.
    National Toxicology Program
    Rep Carcinog; 2002; 10():194. PubMed ID: 15332288
    [No Abstract]   [Full Text] [Related]  

  • 11. Phenacetin abuse related to bladder cancer.
    Fokkens W
    Environ Res; 1979 Oct; 20(1):192-8. PubMed ID: 499168
    [No Abstract]   [Full Text] [Related]  

  • 12. Phenacetin acts as a weak genotoxic compound preferentially in the kidney of DNA repair deficient Xpa mice.
    Luijten M; Speksnijder EN; van Alphen N; Westerman A; Heisterkamp SH; van Benthem J; van Kreijl CF; Beems RB; van Steeg H
    Mutat Res; 2006 Apr; 596(1-2):143-50. PubMed ID: 16464479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotoxicity of phenacetin in the kidney and liver of Sprague-Dawley gpt delta transgenic rats in 26-week and 52-week repeated-dose studies.
    Kawamura Y; Hayashi H; Masumura K; Numazawa S; Nohmi T
    Toxicology; 2014 Oct; 324():10-7. PubMed ID: 25047350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymosin fraction 5 does not influence urinary tract carcinogenesis by phenacetin and N-butyl-N-(4-hydroxybutyl)nitrosamine in NON/Shi mice.
    Murai T; Iwata H; Mori S; Hato F; Kimura S; Kinoshita Y; Wada S; Kishimoto T; Makino S; Oohara T
    Oncol Res; 1995; 7(3-4):139-44. PubMed ID: 8555647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of renal pelvic carcinoma by phenacetin in hydronephrosis-bearing rats of the SD/cShi strain.
    Murai T; Mori S; Machino S; Hosono M; Takeuchi Y; Ohara T; Makino S; Takeda R; Hayashi Y; Iwata H
    Cancer Res; 1993 Sep; 53(18):4218-23. PubMed ID: 8364917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: some miscellaneous pharmaceutical substances.
    IARC Monogr Eval Carcinog Risk Chem Man; 1977; 13():1-255. PubMed ID: 16821
    [No Abstract]   [Full Text] [Related]  

  • 17. Studies on mutagenic and carcinogenic N-substituted aryl compounds: cosmetics and drugs.
    Dybing E; Saxholm HJ; Aune T; Wirth PJ; Thorgeirsson SS
    Natl Cancer Inst Monogr; 1981 Dec; (58):21-26. PubMed ID: 7043276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerance to a lethal dose of phenacetin in phenacetin-pretreated albino rats.
    Carro-Ciampi G
    Toxicol Appl Pharmacol; 1971 Feb; 18(2):269-73. PubMed ID: 5569373
    [No Abstract]   [Full Text] [Related]  

  • 19. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the ability of non-clinical testing strategies currently applied to drugs to detect known human carcinogens.
    Scales MD; Damment SJ; Gatehouse DG
    Adverse Drug React Toxicol Rev; 1992; 11(2):111-22. PubMed ID: 1637961
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.